Abstract

Muscle invasive bladder cancer (MIBC) is a molecularly diverse disease with varied clinical outcomes. Molecular studies typically employ bulk sequencing analysis, giving a transcriptomic snapshot of a section of the tumour. However, tumour tissues are not homogeneous, but are composed of distinct compartments such as the tumour and stroma. To investigate the molecular profiles of bladder cancer, whilst also maintaining the spatial complexity of the tumours, we employed whole transcriptome Digital Spatial Profiling (DSP). With this method we generated a dataset of transcriptomic profiles of tumour epithelium, stroma, and immune infiltrate. With these data we investigate the spatial relationship of molecular subtype signatures and ligand signalling events. We find that Basal/Squamous and Classical subtypes are mostly restricted to tumour regions, while the stroma-rich subtype signatures are abundant within the stroma itself. Additionally, we identify ligand signalling events occurring between tumour, stroma, and immune infiltrate regions, such as immune infiltrate derived GPNMB, which was highly correlated with VEGFA expression within the tumour. These findings give us new insights into the diversity of MIBC at a molecular level and provide a dataset with detailed spatial information that was not available before in bladder cancer research.

A spatial transcriptomics study in bladder cancer investigates the spatial localization of molecular subtype signatures and ligand signaling events.

Details

Title
Digital spatial profiling of the microenvironment of muscle invasive bladder cancer
Author
Eyers, Michael 1   VIAFID ORCID Logo  ; Irlam, Joely 2 ; Marshall, Gayle 1   VIAFID ORCID Logo  ; Smith, Vicky 3   VIAFID ORCID Logo  ; Baker, Alexander 3   VIAFID ORCID Logo  ; Frost, Lucy 1 ; Hoskin, Peter 4   VIAFID ORCID Logo  ; Choudhury, Ananya 5 ; West, Catharine 2   VIAFID ORCID Logo 

 Medicines Discovery Catapult, Cheshire, UK (GRID:grid.500485.c) (ISNI:0000 0004 7699 9615) 
 University of Manchester, Division of Cancer Sciences, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407) 
 CRUK Manchester Centre, Manchester, UK (GRID:grid.500485.c) (ISNI:0000 0004 0612 4047) 
 University of Manchester, Division of Cancer Sciences, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407); Mount Vernon Centre for Cancer Treatment, Northwood, UK (GRID:grid.477623.3) (ISNI:0000 0004 0400 1422) 
 University of Manchester, Division of Cancer Sciences, Manchester, UK (GRID:grid.5379.8) (ISNI:0000 0001 2166 2407); The Christie NHS Foundation Trust, Manchester, UK (GRID:grid.412917.8) (ISNI:0000 0004 0430 9259) 
Pages
737
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3069391471
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.